Solid-state screening and dry powder inhaler development of ziyuglycoside II sodium salt for enhanced bioavailability
文献类型：期刊论文
| 作者 | Zhang, Hanwen2,4; Wang, Siwen1,2; Slimani, Sara1,2; Lv, Yuting2; Nie, Qin2,4; Cao, Zeying1,2; Yang, Siying1,2; Bao, Haojie2,4; Wang, Caifen2,4; Chen, Xintao3 |
| 刊名 | INTERNATIONAL JOURNAL OF PHARMACEUTICS
 |
| 出版日期 | 2025-08-20 |
| 卷号 | 681页码:11 |
| 关键词 | Bioavailability Dry powder inhaler Saponin Solid-state screening Ziyuglycoside II sodium salt |
| ISSN号 | 0378-5173 |
| DOI | 10.1016/j.ijpharm.2025.125868 |
| 通讯作者 | Feng, Yulin(fengyulin2003@126.com) ; Wu, Li(wuli@simm.ac.cn) ; Zhang, Jiwen(jwzhang@simm.ac.cn) |
| 英文摘要 | The pharmacological effects of ziyuglycoside II (ZYG II), a saponin derived from Sanguisorba officinalis L., were partially limited by low oral bioavailability (< 5 %) attributable to its poor water solubility, low membrane permeability and extensive first-pass metabolism. To enhance solubility, salt form was selected as ZYG II sodium salt (ZYG-II-Na) in this study, with systematic screening and characterization of its solid forms. To improve the bioavailability, the dry powder inhaler (DPI) of ZYG-II-Na was designed using the optimized solid form. Three crystalline forms (I, II, and III) and two amorphous forms (I and II) of ZYG-II-Na were identified and thoroughly characterized by structural analysis, stability assessment, powder evaluation, in vitro solubility studies, and in vivo pharmacokinetic assessments. Among these, amorphs I and II maintained supersaturation for longer period of time in purified water and Gamble's solution, respectively, indicating enhanced solubility stability. Crystal III exhibited remarkable humidity stability, whereas other solid forms required controlled humidity conditions for storage. The aerodynamic properties of ZYG-II-Na support its suitability for pulmonary delivery. In rats, the oral bioavailability of crystal I was only 3.53 %, whereas the bioavailability of its DPI administration increased to 8.54 %. Remarkably, amorph II further enhanced absorption, reaching an absolute bioavailability of 16.8 %, representing a 4.8-fold enhancement over oral administration. In conclusion, the cooperation of solid form optimization and inhalation delivery successfully overcomes the key barriers associated with poor bioavailability of saponin ZYG II. |
| WOS关键词 | SANGUISORBA-OFFICINALIS L. ; CELL-CYCLE ARREST ; APOPTOSIS ; SOLUBILITY |
| 资助项目 | National Natural Science Foundation of China[82273863] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001520681000002 |
| 出版者 | ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/318684]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Feng, Yulin; Wu, Li; Zhang, Jiwen |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Delivery Syst, Shanghai 201210, Peoples R China 3.Jiangxi Univ Chinese Med, Natl Pharmaceut Engn Ctr Solid Preparat Chinese He, Nanchang 330004, Peoples R China 4.Shenyang Pharmaceut Univ, Coll Pharm, Shenyang 110016, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Hanwen,Wang, Siwen,Slimani, Sara,et al. Solid-state screening and dry powder inhaler development of ziyuglycoside II sodium salt for enhanced bioavailability[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS,2025,681:11. |
| APA | Zhang, Hanwen.,Wang, Siwen.,Slimani, Sara.,Lv, Yuting.,Nie, Qin.,...&Zhang, Jiwen.(2025).Solid-state screening and dry powder inhaler development of ziyuglycoside II sodium salt for enhanced bioavailability.INTERNATIONAL JOURNAL OF PHARMACEUTICS,681,11. |
| MLA | Zhang, Hanwen,et al."Solid-state screening and dry powder inhaler development of ziyuglycoside II sodium salt for enhanced bioavailability".INTERNATIONAL JOURNAL OF PHARMACEUTICS 681(2025):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。